Dechra Pharmaceuticals PLC is a global leader in veterinary pharmaceuticals, dedicated exclusively to the veterinary market. Founded in 1997, the company has a rich history dating back to 1819. Dechra develops, manufactures, and markets high-quality pharmaceutical products and services aimed at improving animal health and welfare. It operates in 24 countries and distributes products in over 50 countries. The company offers a diverse portfolio of prescription-only veterinary medicines for companion animals and horses, focusing on areas such as endocrinology, dermatology, and critical care. Dechra also provides water-soluble antibiotics, poultry vaccines, and specialized diets. Its services division includes laboratories that support veterinary diagnostics. With a strong emphasis on understanding veterinarians needs, Dechra provides training and scientific resources to enhance animal care.
Virtual Radiologic (vRad) is a technology-enabled national radiology practice working in partnership with local radiologists and hospitals to optimize radiology’s pivotal role in patient care. vRad’s more than 400 radiologists serve 2,000+ facilities, reading 7 million studies annually. Delivering access to extensive subspecialty coverage, vRad contributes to improved quality of patient care. And with its next-generation technology, vRad enhances productivity, helping to lower the overall cost of care while expediting time to accurate diagnosis and treatment.
The world leader in addiction treatment with over 20 years of experience and a patient-focused approach. We didn`t become the world leader in addiction treatment overnight. Our endeavor started small, with one singular focus – to intimately understand the journey of individuals suffering with addiction. People with addiction are often stereotyped and discounted, creating an environment where many are under-diagnosed, undertreated and under-supported. They`re often unaware of their treatment options, have limited access to treatment, or simply don`t seek it out because they`re afraid of being stigmatized. Since our inception, we have actively partnered with healthcare professionals, the public health community, policy makers, and payers to humanize people suffering from addiction and to treat addiction as a chronic, relapsing medical condition rather than a social disorder. We believe that people with addiction should be treated as patients, just like people with other chronic diseases. The past two decades have been marked by strong growth and an expansion into more than 40 countries. While treatment for opioid use disorder has seen much innovation, we at Indivior are building on our intimate understanding of the patient journey to further advance addiction treatment including opiate overdose, alcohol use disorders, and co-occurring conditions such as schizophrenia by bringing to market novel treatment solutions worldwide. We at Indivior are on an endeavor – one that is focused on individual patients around the world. Our name reflects this as the key words individual and endeavor harmoniously blend together. It represents and empathizes with the often difficult journey each individual patient takes to overcome the challenges of addiction – a chronic relapsing disease. The patient continues to drive our decisions. Our guiding principles foster a corporate culture of trust, innovation, and a pioneering spirit. We work with the urgency and zeal required to achieve our vision that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction.
Cypress Bioscience, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Alamar Biosciences is a biotechnology company that has developed a next generation proteomic platform with ultra high sensitivity and multiplexing capability for plasma protein detection and liquid biopsies.